Champions Oncology Inc
F:2I3

Watchlist Manager
Champions Oncology Inc Logo
Champions Oncology Inc
F:2I3
Watchlist
Price: 5.45 EUR -3.54% Market Closed
Market Cap: 74.1m EUR

Intrinsic Value

The intrinsic value of one 2I3 stock under the Base Case scenario is 6.36 EUR. Compared to the current market price of 5.45 EUR, Champions Oncology Inc is Undervalued by 14%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

2I3 Intrinsic Value
6.36 EUR
Undervaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Champions Oncology Inc

What is Valuation History?
Compare 2I3 to

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about CSBR?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Champions Oncology Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Champions Oncology Inc

Current Assets 22.4m
Cash & Short-Term Investments 9.8m
Receivables 11.2m
Other Current Assets 1.4m
Non-Current Assets 10m
PP&E 9.5m
Intangibles 335k
Other Non-Current Assets 185k
Efficiency

Free Cash Flow Analysis
Champions Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Champions Oncology Inc

Revenue
56.9m USD
Cost of Revenue
-28.4m USD
Gross Profit
28.6m USD
Operating Expenses
-23.7m USD
Operating Income
4.8m USD
Other Expenses
-145k USD
Net Income
4.7m USD
Fundamental Scores

2I3 Profitability Score
Profitability Due Diligence

Champions Oncology Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

49/100
Profitability
Score

Champions Oncology Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

2I3 Solvency Score
Solvency Due Diligence

Champions Oncology Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
55/100
Solvency
Score

Champions Oncology Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

2I3 Price Targets Summary
Champions Oncology Inc

Wall Street analysts forecast 2I3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 2I3 is 9.98 EUR with a low forecast of 9.88 EUR and a high forecast of 10.27 EUR.

Lowest
Price Target
9.88 EUR
81% Upside
Average
Price Target
9.98 EUR
83% Upside
Highest
Price Target
10.27 EUR
88% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Champions Oncology Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CSBR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

CSBR Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one 2I3 stock?

The intrinsic value of one 2I3 stock under the Base Case scenario is 6.36 EUR.

Is 2I3 stock undervalued or overvalued?

Compared to the current market price of 5.45 EUR, Champions Oncology Inc is Undervalued by 14%.

Back to Top